System for controlled administration of a substance from a human-body-implanted infusion device

422 million people worldwide have diabetes, of which between 5% and 10% are DT1 (Melmed S, et al., 2011). Diabetes deaths will double between 2005 and 2040 (WHO). The size of the global market in 2017 is = USD 56 billion with a CAGR of 6.25% in 2018-2023. Eg the blood glucose test costs ~ £ 175 million / year for the UK national health service (NHS). The device is an artificial organ for delivering an adequate amount of insulin in response to selectable parameters recorded by a blood glucose sensor. The device is rechargeable with ingestible capsules containing insulin...other